Jecure Therapeutics

Jecure Therapeutics Focuses on Discovering New Therapies for NASH and Liver Fibrosis. The scientific founder of Jecure is Dr. Ariel Feldstein, Chair of the Department of Gastroenterology at the University of California, San Diego School of Medicine and a leading physician-scientist in the field of hepatology. Operating in San Diego, California's biotech hub, Jecure combines emerging NASH biology from Dr. Feldstein’s lab, a proprietary liver disease platform, and an elite discovery team composed of seasoned pharmaceutical/biotech scientists. Jecure’s lead program has identified small molecule inhibitors of the NLRP3 inflammasome, a novel target and pro-inflammatory driver in NASH. Jecure is backed by top life science investor Versant Ventures.